UB Paderborn / Katalog / Suche / in CDI

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Journal of clinical oncology, 2021-10, Vol.39 (30), p.3391-3402

2021

Volltextzugriff (PDF)

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

Journal of thoracic oncology, 2021-12, Vol.16 (12), p.2091-2108

2021

Volltextzugriff (PDF)

RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer

British journal of cancer, 2019-07, Vol.121 (3), p.211-217

2019

Volltextzugriff (PDF)

Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer

Molecular cancer therapeutics, 2021-12, Vol.20 (12), p.2577-2584

2021

Volltextzugriff (PDF)

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

Journal of clinical oncology, 2021-09, Vol.39 (26), p.2914-2925

2021

Volltextzugriff (PDF)

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer

Future oncology (London, England), 2022-02, Vol.18 (6), p.639-647

2022

Volltextzugriff (PDF)

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

Journal of clinical oncology, 2013-02, Vol.31 (4), p.412-419

2013

Volltextzugriff (PDF)

A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer

Medical oncology (Northwood, London, England), 2017-06, Vol.34 (6), p.103, Article 103

2017

Volltextzugriff (PDF)

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

Journal of clinical oncology, 2012-06, Vol.30 (18), p.2248-2255

2012

Volltextzugriff (PDF)

A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2022-01, Vol.163, p.19-26

2022

Volltextzugriff (PDF)

Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor

Clinical lung cancer, 2018-11, Vol.19 (6), p.518-530.e7

2018

Volltextzugriff (PDF)

Has the Enemy "MET" Its Match? Subgroup Analysis Results from VISION Study

Clinical cancer research, 2022-03, Vol.28 (6), p.1055-1057

2022

Volltextzugriff (PDF)

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

The New England journal of medicine, 2023-01, Vol.388 (1), p.44-54

2023

Volltextzugriff (PDF)

Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer

Frontiers in oncology, 2023-08, Vol.13, p.1215524-1215524

2023

Volltextzugriff (PDF)

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation

The New England journal of medicine, 2022-07, Vol.387 (2), p.120-131

2022

Volltextzugriff (PDF)

Detection of NRG1 Gene Fusions in Solid Tumors

Clinical cancer research, 2019-08, Vol.25 (16), p.4966-4972

2019

Volltextzugriff (PDF)

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

Cancer discovery, 2021-07, Vol.11 (7), p.1688-1699

2021

Volltextzugriff (PDF)

A retrospective observational study of the natural history of advanced non–small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease

Lung cancer (Amsterdam, Netherlands), 2021-09, Vol.159, p.1-9

2021

Volltextzugriff (PDF)

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation

Journal of clinical oncology, 2023-09, Vol.41 (25), p.4097-4106

2023

Volltextzugriff (PDF)

Adagrasib in Non-Small-Cell Lung Cancer. Reply

The New England journal of medicine, 2022-09, Vol.387 (13), p.1238-1239

2022

Volltextzugriff (PDF)

A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Clinical cancer research, 2020-12, Vol.26 (23), p.6132-6140

2020

Volltextzugriff (PDF)

Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results

Nature medicine, 2022-08, Vol.28 (8), p.1619-1629

2022

Volltextzugriff (PDF)

Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Clinical cancer research, 2021-12, Vol.27 (23), p.6413-6423

2021

Volltextzugriff (PDF)

The Use of Chemotherapy in Soft‐Tissue Sarcomas

The oncologist (Dayton, Ohio), 2002-01, Vol.7 (4), p.348-359

2002

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer

Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer

Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy

A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer

Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor

Has the Enemy "MET" Its Match? Subgroup Analysis Results from VISION Study

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation

Detection of NRG1 Gene Fusions in Solid Tumors

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

A retrospective observational study of the natural history of advanced non–small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation

Adagrasib in Non-Small-Cell Lung Cancer. Reply

A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results

Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

The Use of Chemotherapy in Soft‐Tissue Sarcomas

Suchergebnisse filtern